Evaluation of 18F-fluciclovine (FACBC) PET/MR Uptake in Participants With Glioma
Status:
Recruiting
Trial end date:
2021-09-30
Target enrollment:
Participant gender:
Summary
This is a pilot study to assess the ability of [F-18]fluciclovine to differentiate
pseudoprogression from progression in participants after therapy, at imaging time points
within the 12 week interval post chemoradiation. [F-18]fluciclovine. PET will be obtained at
the time point in the 12 week interval in which MRI demonstrates increase in enhancing volume
with the differential diagnosis of pseudoprogression versus tumor progression. At the same
time point (at least 6 hours after [F-18]fluciclovine or up to 3 days) F-18 FDG will also be
performed consistent with standard clinical practice. The verification of pseudoprogression
versus tumor progression will be determined by the regression of enhancing lesion on
subsequent MRI imaging obtained as part of standard care.